New drug for chronic hives tested in everyday practice

NCT ID NCT07358780

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal is to see if remibrutinib works as well in real-world settings as it does in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remibrutinib
What this could lead to: If successful, this could show that remibrutinib is a safe and effective option for people with chronic hives that are not controlled by standard antihistamines.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. Remibrutinib is still new, and long-term risks are not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Cleaver Dermatology
RECRUITING

Kirksville, Missouri, 63501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.